Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*

Abstract

Drotrecogin alfa (activated) demonstrated significant improvements in organ function compared with placebo in a large phase 3 clinical trial that has shown a mortality benefit in patients with severe sepsis.